Cover Image
Market Research Report

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 398830
Published Content info 180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019
Published: November 25, 2019 Content info: 180 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 25 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 4 and 1 molecule, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11543IDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H5N1 Subtype Infections - Overview
  • Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
    • Abivax SA
    • Abzyme Therapeutics LLC
    • AIM ImmunoTech Inc
    • Akshaya Bio Inc
    • Altimmune Inc
    • Aphios Corp
    • AusBio Ltd
    • BiondVax Pharmaceuticals Ltd
    • CEL-SCI Corp
    • Chicago Biosolutions Inc
    • CHO Pharma Inc
    • Cocrystal Pharma Inc
    • Curevac AG
    • Declion Pharmaceuticals Inc
    • FluGen Inc
    • Gamaleya Federal Research Center of Epidemiology and Microbiology
    • Gamma Vaccines Pty Ltd
    • Global BioLife Inc Ltd
    • Greffex Inc
    • i2 Pharmaceuticals Inc
    • Inovio Pharmaceuticals Inc
    • Johnson & Johnson
    • Kineta Inc
    • Medicago Inc
    • Medigen Inc
    • NanoViricides Inc
    • New Amsterdam Sciences Inc
    • OPKO Health Inc
    • PeptiDream Inc
    • Seqirus Ltd
    • Shionogi & Co Ltd
    • TechnoVax Inc
    • Tria Bioscience Corp
    • Vacthera BioTech GmbH
    • Vaxart Inc
    • Vaxine Pty Ltd
    • Virion Biotherapeutics
    • Virvio Inc
  • Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
    • (oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABX-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alferon LDO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baloxavir marboxil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-42344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHOS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-7302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GamFluVac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GREFLU/VIE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-36.6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infectious disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A /Vietnam/1203/04 (H5N1)] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-2009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDG-8972 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAS-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nasovax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Influenza Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pimodivir hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDEE FLU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Influenza Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVX-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VGX-3400X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VH-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTH-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 12, 2019: Vaxart to present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
      • Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.
      • Mar 06, 2019: FDA accepts Genentech's supplemental new drug application for XOFLUZA (baloxavir marboxil) for the treatment of influenza in people at high risk of complications
      • Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
      • Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine
      • Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
      • Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
      • Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant
      • Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
      • Sep 30, 2015: BiondVax Initiates a Phase Iib Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
      • Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.
      • Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine
      • Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting
      • Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company's Universal Flu Vaccine
      • Jan 21, 2014: BiondVax's universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 5: Products under Development by Companies, H2 2019
  • Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 8: Products under Development by Universities/Institutes, H2 2019
  • Table 9: Number of Products by Stage and Target, H2 2019
  • Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 11: Number of Products by Stage and Route of Administration, H2 2019
  • Table 12: Number of Products by Stage and Molecule Type, H2 2019
  • Table 13: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abivax SA, H2 2019
  • Table 14: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H2 2019
  • Table 15: Influenza A Virus, H5N1 Subtype Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
  • Table 16: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2019
  • Table 17: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2019
  • Table 18: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2019
  • Table 19: Influenza A Virus, H5N1 Subtype Infections - Pipeline by AusBio Ltd, H2 2019
  • Table 20: Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2019
  • Table 21: Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2019
  • Table 22: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, H2 2019
  • Table 23: Influenza A Virus, H5N1 Subtype Infections - Pipeline by CHO Pharma Inc, H2 2019
  • Table 24: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
  • Table 25: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H2 2019
  • Table 26: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Declion Pharmaceuticals Inc, H2 2019
  • Table 27: Influenza A Virus, H5N1 Subtype Infections - Pipeline by FluGen Inc, H2 2019
  • Table 28: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, H2 2019
  • Table 29: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, H2 2019
  • Table 30: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Global BioLife Inc Ltd, H2 2019
  • Table 31: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Greffex Inc, H2 2019
  • Table 32: Influenza A Virus, H5N1 Subtype Infections - Pipeline by i2 Pharmaceuticals Inc, H2 2019
  • Table 33: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Table 34: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2019
  • Table 35: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2019
  • Table 36: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2019
  • Table 37: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Inc, H2 2019
  • Table 38: Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2019
  • Table 39: Influenza A Virus, H5N1 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, H2 2019
  • Table 40: Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2019
  • Table 41: Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2019
  • Table 42: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Seqirus Ltd, H2 2019
  • Table 43: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2019
  • Table 44: Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2019
  • Table 45: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Tria Bioscience Corp, H2 2019
  • Table 46: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vacthera BioTech GmbH, H2 2019
  • Table 47: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2019
  • Table 48: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2019
  • Table 49: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Virion Biotherapeutics, H2 2019
  • Table 50: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Virvio Inc, H2 2019
  • Table 51: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019
  • Table 52: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Table 53: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Table 54: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..3), H2 2019
  • Table 55: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..4), H2 2019
  • Table 56: Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top